AIDSVAX B/E vaccine

BIOLOGICAL3 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

HIV Infections

Phase 1

Evaluating the Safety and Immune Response to Two HIV Vaccine Regimens in Healthy, HIV-Uninfected Adults in the United States and South Africa

WithdrawnNCT01927835

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Updated: 2021-10-15

Evaluating the Safety and Immune Response to Different Combinations of the DNA-HIV-PT123 and AIDSVAX® B/E Vaccines in Healthy, HIV-Uninfected Adults

CompletedNCT02207920

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2014-07-31End: 2015-12-31Updated: 2021-10-15

Evaluating the Immunogenicity of the AIDSVAX B/E Vaccine and the MVA/HIV62B Vaccine in Healthy, HIV-1-Uninfected Adults Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205

CompletedNCT02852005

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2017-01-31End: 2019-10-29Updated: 2022-08-08

Related Papers

A polyvalent DNA prime with matched polyvalent protein/GLA-SE boost regimen elicited the most robust and broad IgG and IgG3 V1V2 binding antibody and CD4+ T cell responses among 13 HIV vaccine trials

Emerging Microbes & Infections2025-04-071 citations

Mixed Origins: HIV gp120-Specific Memory Develops from Pre-Existing Memory and Naive B Cells Following Vaccination in Humans

AIDS Research and Human Retroviruses2023-02-104 citations

Sequence and vector shapes vaccine induced antibody effector functions in HIV vaccine trials

PLoS Pathogens2021-11-292 citations

DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial

Journal of Clinical Investigation2019-09-3035 citations